Second line therapy with Docetaxel + lanreotide in patients with hormone refractory metastatic prostate cancer and progression during chemotherapy of the line with docetaxel. Phase II study.

Trial Profile

Second line therapy with Docetaxel + lanreotide in patients with hormone refractory metastatic prostate cancer and progression during chemotherapy of the line with docetaxel. Phase II study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Lanreotide (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Most Recent Events

    • 26 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top